<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978913</url>
  </required_header>
  <id_info>
    <org_study_id>AA 0914</org_study_id>
    <nct_id>NCT00978913</nct_id>
  </id_info>
  <brief_title>Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma</brief_title>
  <official_title>Evaluation of Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA as a Treatment for Patients With Metastatic Breast Cancer or Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inge Marie Svane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to evaluate the toxicity of the vaccine and the combination&#xD;
      of the vaccine and Cyclophosphamide, and to evaluate the immune response induced by the&#xD;
      vaccine. The secondary aim is to investigate the clinical tumour response and duration of&#xD;
      tumour and immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I trial. Single center study; patients will be referred to the study center from other&#xD;
      institutions in Denmark. 14 patients will be included in this phase I trial DC vaccination&#xD;
      regime consists of primary 6 biweekly intradermal injections with transfected dendritic&#xD;
      cells, followed by monthly injections until progression; Cyclophosphamide is used as vaccine&#xD;
      adjuvant.&#xD;
&#xD;
      Defined procedures are employed for generation of autologous dendritic cells for clinical&#xD;
      application in a classified laboratory. Unmobilized leukapheresis will be used for isolation&#xD;
      of large-scale mononuclear cells, and dendritic cells will be generated from monocytes by&#xD;
      cytokine stimulation and transfected with mRNA encoding for hTERT, survivin and p53 if the&#xD;
      tumour express p53. Frozen preparations of dendritic cells will be prepared using automated&#xD;
      cryopreservation. Each patient will receive a minimum of 1x106 dendritic cells per treatment&#xD;
      supplemented with Cyclophosphamide 50 mg twice a day every second week. Toxicity including&#xD;
      autoimmunity will be evaluated using the Common Toxicity Criteria (CTC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the toxicity of the vaccine in combination with Cyclophosphamide</measure>
    <time_frame>biweekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to investigate the clinical tumor response and the duration</measure>
    <time_frame>after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the duration of tumor and immunoresponse</measure>
    <time_frame>3, 6, 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate immune response</measure>
    <time_frame>at 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>DC vaccination and Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC vaccine</intervention_name>
    <description>DC vaccination, one vaccine biweekly</description>
    <arm_group_label>DC vaccination and Cyclophosphamide</arm_group_label>
    <other_name>dendritic cell vaccine</other_name>
    <other_name>Cyclophosphamide, Sendoxan®, Baxter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological verified metastatic breast cancer or malignant melanoma, in progression&#xD;
&#xD;
          2. ≥ 18 years&#xD;
&#xD;
          3. the patient must be habil&#xD;
&#xD;
          4. Performance status ≤ 1 on Zubrod-ECOG-WHO-scale&#xD;
&#xD;
          5. Leukocytes and platelets must be ≥normal. Hg ≥ 6.0&#xD;
&#xD;
          6. creatinin must be normal&#xD;
&#xD;
          7. Liverparametre &lt;2.5 x normal. Bilirubin &lt;30&#xD;
&#xD;
          8. Expected survival &gt; 3 months&#xD;
&#xD;
          9. Informed consent&#xD;
&#xD;
        11. At least one measurable lesion according to RECIST criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indication for chemotherapy&#xD;
&#xD;
          2. Other malignancies&#xD;
&#xD;
          3. Brain metastases&#xD;
&#xD;
          4. severe medical condition&#xD;
&#xD;
          5. Acute/chronic infection with ex. HIV, hepatitis, tuberculose&#xD;
&#xD;
          6. Severe allergy&#xD;
&#xD;
          7. Autoimmune disease&#xD;
&#xD;
          8. Other treatment with immune suppressing agents, other anticancer agents or&#xD;
             experimental drugs&#xD;
&#xD;
          9. Uncontrolled hypercalcemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge Marie Svane, prof.MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Oncology, Herlev University Hospital, Herlev Ringvej 75,2730 Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>Dk 2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inge Marie Svane</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>dendritic cell</keyword>
  <keyword>cancervaccine</keyword>
  <keyword>breast cancer</keyword>
  <keyword>malignant melanoma</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

